Rubius Therapeutics Inc expected to post a loss of 59  cents a share - Earnings Preview

Rubius Therapeutics

23/02/2022 19:13

* Rubius Therapeutics Inc  RUBY.OQ   RUBY.O  is expected
to show
no change in quarterly revenue when it reports  results on
February 25. 
    * ​Refinitiv's mean analyst estimate for Rubius Therapeutics
Inc
is for a loss of 59 cents per share. For the same quarter last
year, the company reported a loss of 50 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Rubius
Therapeutics Inc is $17.5​, about 72.1% above​ its last closing
price of $4.89. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.57       -0.57      -0.55     Beat    3.2
 Jun. 30 2021  -0.50       -0.49      -0.56     Missed  -14.7
 Mar. 31 2021  -0.53       -0.52      -0.51     Beat    1.3​
 Dec. 31 2020  -0.52       -0.49      -0.50     Missed  -1
 ​​Sep.        -0.49       -0.49      -0.51     Missed  -3.4
 30 2020                                                
 Jun. 30 2020  -0.50       -0.50      -0.47     Beat    6.5​
 Mar. 31 2020  -0.55       -0.56      -0.60     Missed  -8
 Dec. 31 2019  -0.63       -0.60      -0.56     Beat    7
 This summary was machine generated February 23 at 19:13 GMT. 
All figures in US dollars  unless otherwise stated